The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Repurposing metformin for cancer treatment: current clinical studies
Open accessAbstract
// Young Kwang Chae 1,2,3 , Ayush Arya 3 , Mary-Kate Malecek 3 , Daniel Sanghoon Shin 4 , Benedito Carneiro 1,2,3 , Sunandana Chandra 1,2,3 , Jason Kaplan 1,2,3 , Aparna Kalyan 1,2,3 , Jessica K. Altman 1,2,3 , Leonidas Platanias 1,2,3,5 and Francis Giles 1,2,3 1 Northwestern Medicine Developmental Therapeutics Institute, Chicago, IL, USA 2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 3 Northwestern University Feinberg School of Medicine, Chicago, IL, USA 4 David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA 5 Division of Hematology-Oncology, Department of Medicine, Jesse Brown VA Medical Center, Chicago, IL, USA Correspondence to: Young Kwang Chae, email: // Keywords : metformin, clinical trials, cancer Received : September 20, 2015 Accepted : March 06, 2016 Published : March 19, 2016 Abstract In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
The assessment of insulin resistance in man
Wallace, T. M., & Matthews, D. R. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00745.x · Cited by 677
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 557
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., & Dennis, P. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0055 · Cited by 408
Mortality After Incident Cancer in People With and Without Type 2 Diabetes
Currie, C. J., Poole, C. D., Jenkins-Jones, S., Gale, E. A. M., Johnson, J. A., & Morgan, C. L. (2012) · Diabetes Care · doi:10.2337/dc11-1313 · Cited by 398
Cantrell, L. A., Zhou, C., Mendivil, A., Malloy, K. M., Gehrig, P. A., & Bae-Jump, V. L. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.024 · Cited by 331
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Hadrup, S., Donia, M., & thor Straten, P. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 310
Metformin: Multi-faceted protection against cancer
Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302
Moutschen, M. P., Scheen, A. J., & Lefèbvre, P. J. (1992) · PubMed · Cited by 301
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
Song, C. W., Lee, H., Dings, R. P. M., Williams, B., Powers, J., Santos, T. D., Choi, B.-H., & Park, H. J. (2012) · Scientific Reports · doi:10.1038/srep00362 · Cited by 280
Storozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 273
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270
Vazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250
Alfarouk, K. O., Verduzco, D., Rauch, C., Muddathir, A. K., Bashir, A. H. H., Elhassan, G. O., Ibrahim, M. E., Orozco, J. D. P., Cardone, R. A., Reshkin, S. J., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.109 · Cited by 245
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bonanni, B., Puntoni, M., Cazzaniga, M., Pruneri, G., Serrano, D., Guerrieri-Gonzaga, A., Gennari, A., Trabacca, M. S., Galimberti, V., Veronesi, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3769 · Cited by 244
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study
Niraula, S., Dowling, R. J. O., Ennis, M., Chang, M. C., Done, S. J., Hood, N., Escallon, J., Leong, W. L., McCready, D. R., Reedijk, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2223-1 · Cited by 238
Zakikhani, M., Blouin, M.-J., Piura, E., & Pollak, M. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0763-9 · Cited by 213
Green, A. S., Chapuis, N., Trovati Maciel, T., Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269837 · Cited by 199
Metformin targets ovarian cancer stem cells in vitro and in vivo
Shank, J. J., Yang, K., Ghannam, J., Cabrera, L., Johnston, C. J., Reynolds, R. K., & Buckanovich, R. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.07.115 · Cited by 189
Glioma-Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK
Sato, A., Sunayama, J., Okada, M., Watanabe, E., Seino, S., Shibuya, K., Suzuki, K., Narita, Y., Shibui, S., Kayama, T., et al. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0058 · Cited by 184
Barbee, M. S., Ogunniyi, A., Horvat, T. Z., & Dang, T.-O. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015586218 · Cited by 179
Yoshida, S., Hong, S., Suzuki, T., Nada, S., Mannan, A. M., Wang, J., Okada, M., Guan, K., & Inoki, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.238014 · Cited by 161
Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A
Martin, M. J., Hayward, R., Virós, A., & Marais, R. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0280 · Cited by 152
Zhang, Z., & Li, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12267 · Cited by 149
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144
Mohammed, A., Janakiram, N. B., Brewer, M., Ritchie, R. L., Marya, A., Lightfoot, S., Steele, V. E., & Rao, C. V. (2013) · Translational Oncology · doi:10.1593/tlo.13556 · Cited by 142
Schuler, K., Rambally, B. S., DiFurio, M. J., Sampey, B. P., Gehrig, P. A., Makowski, L., & Bae-Jump, V. L. (2014) · Cancer Medicine · doi:10.1002/cam4.353 · Cited by 138
Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial
Mitsuhashi, A., Kiyokawa, T., Sato, Y., & Shozu, M. (2014) · Cancer · doi:10.1002/cncr.28853 · Cited by 132
Zhou, X., Chen, J., Gao, Y., Deng, M., Liu, H., Liang, M., Shi, B., Fu, X., Chen, Y., Chen, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6418 · Cited by 115
Laskov, I., Drudi, L. M., Beauchamp, M.-C., Yasmeen, A., Ferenczy, A. S., Pollak, M., & Gotlieb, W. H. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.014 · Cited by 104
Hadad, S. M., Coates, P. J., Jordan, L. B., Dowling, R. J. O., Chang, M. C., Done, S. J., Purdie, C. A., Goodwin, P. J., Stambolic, V., Moulder-Thompson, S. L., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3307-5 · Cited by 98
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients
Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E., & Grassi, G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01480.x · Cited by 86
Groop, P. (2000) · PubMed · Cited by 83
The effect of metformin on apoptosis in a breast cancer presurgical trial
Cazzaniga, M. E., DeCensi, A., Pruneri, G., Puntoni, M., Bottiglieri, L., Varricchio, C., Guerrieri‐Gonzaga, A., Gentilini, O., Pagani, G., Dell’Orto, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.657 · Cited by 82
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kalinsky, K. M., Crew, K. D., Refice, S., Xiao, T., Wang, A., Feldman, S. M., Taback, B., Ahmad, A., Cremers, S., Hibshoosh, H. H., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.889706 · Cited by 79
A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer
Joshua, A. M., Zannella, V. E., Downes, M. R., Bowes, B., Hersey, K. M., Koritzinsky, M., Schwab, M. G., Hofmann, U., Evans, A., van der Kwast, T., et al. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.20 · Cited by 75
Metformina – mechanizmy działania i zastosowanie w terapii cukrzycy typu 2[i][/i]
Grzybowska, M., Bober, J., & Olszewska, M. (2011) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.941655 · Cited by 53
A phase I study of temsirolimus and metformin in advanced solid tumours
MacKenzie, M. J., Ernst, S., Johnson, C., & Winquist, E. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9570-8 · Cited by 52
Deng, D., Yang, Y., Tang, X., Skrip, L., Qiu, J., Wang, Y., & Zhang, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2645 · Cited by 50
Braghiroli, M. I., Ferrari, A. C. R. D. C., Pfiffer, T., Alex, A. K., Nebuloni, D. R., Cagnacci, A. Q. C., Capareli, F. C., Leite, L. A. S., Lobo, J., Hoff, P. M., et al. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.563 · Cited by 48
Matthaei, S., & Greten, H. (1991) · PubMed · Cited by 43
Ferrari, A. C. R. D. C., Pfiffer, T., Alex, A. K., Nebuloni, D. R., Carneiro, A. Q., Capareli, F. C., Leite, L. A. S., Braghiroli, M. I., Lobo, J., Hoff, P. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.e15196 · Cited by 12
Association of the metformin with the risk of lung cancer: a meta-analysis.
Wang, L., Song, Y., Wu, G., & Yuan, D. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.08.01 · Cited by 11
Wilmink, J. W., Kordes, S., Zwinderman, A. H., Mathôt, R. A. A., Punt, C. J. A., & Richel, D. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4021 · Cited by 10
Pembrolizumab Shows Potential in Breast Cancer
(2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2014-184 · Cited by 5
Cited by
Fatty acid synthase (FASN) as a therapeutic target in breast cancer
Menendez, J. A., & Lupu, R. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1381087 · Cited by 293
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression
Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13007 · Cited by 239
Gallagher, E. J., & LeRoith, D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0295-5 · Cited by 241
López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207
Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162
Metadata
- Authors
- Chae, Y. K., Arya, A., Malecek, M.-K., Shin, D. S., Carneiro, B., Chandra, S., Kaplan, J., Kalyan, A., Altman, J. K., Platanias, L., & Giles, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-19
- Volume
- 7
- Issue
- 26
- Pages
- 40767-40780
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2323045903
- Cited by
- 316
- References
- 57
- FWCI
- 22.57
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.